Ceritinib appears to be effective against advanced ALK-positive non-small cell lung cancer (NSCLC), find researchers. The results of a phase 1 clinical trial conducted at centers in 11 countries are reported in the March 27 iNew England Journal of Medicine/i.
"Crizotinib has become a standard treatment agent for patients with advanced, ALK-rearranged NSCLC, but patients invariably develop resistance, leaving their treatment options limited," says Alice Shaw, MD, PhD, of the Massachusetts ...
Ceritinib appears to be effective against advanced ALK-positive non-small cell lung cancer (NSCLC), find researchers. The results of a phase 1 clinical trial conducted at centers in 11 countries are reported in the March 27 iNew England Journal of Medicine/i.
"Crizotinib has become a standard treatment agent for patients with advanced, ALK-rearranged NSCLC, but patients invariably develop resistance, leaving their treatment options limited," says Alice Shaw, MD, PhD, of the Massachusetts ...